Skip to main content

Table 3 Subgroup analysis of MTHFR polymorphisms rs1801133 and rs1801131

From: A meta-analysis on the susceptibility to the development of bladder cancer in the presence of DNMT3A, DNMT3B, and MTHFR gene polymorphisms

SNPs

Genetic model

Group

Number of studies

Asso P-val

OR 95% CI

Rs1801133

 

Geographic region

   
 

T vs. C

Western Asia

1

0.016

2.36 [1.168–4.779]

 

TT vs. TC + CC

North African

3

0.013

0.52 [0.311–0.872]

 

TT + TC vs. CC

South America

1

0.046

0.56 [0.320–0.990]

  

Western Asia

1

0.036

2.38 [1.055–5.400]

  

South America

1

0.033

0.556 [0.323–0.956]

 

TT vs. TC

North African

3

0.003

0.448 [0.261–0.769]

 

TC vs. CC

South America

1

0.026

0.506 [0.277–0.923]

  

Genotyping methods

   
 

TC vs. CC

PCR–RFLP

12

0.040

1.12 [1.005–1.269]

Rs1801131

 

Geographic region:

   
 

CC + CA vs. AA

North African

1

0.047

1.68 [1.006–2.832]

 

CC vs. CA

North American

3

0.039

0.71 [0.523–0.984]

 

CA vs. AA

North African

1

0.025

1.86 [1.079–3.210]

  

Genotyping methods

   
 

C vs. A

PCR-Sequencing

1

0.004

0.69 [0.537–0.892]

 

CC vs. CA + AA

Taqman SNP genotyping assays

1

0.027

0.48 [0.250–0.920]

 

CC + CA vs. AA

PCR-Sequencing

1

0.003

0.53 [0.347–0.815]

 

CC vs. AA

PCR-Sequencing

1

0.003

0.45 [0.269–0.777]

 

CC vs. CA

Taqman SNP genotyping assays

1

0.011

0.419 [0.213–0.824]

 

CA vs. AA

PCR-Sequencing

1

0.013

0.56 [0.364–0.890]

  1. The bolds pointed to models that had statistically significant associations with BC